Jeff Ajer, BioMarin chief commercial officer
January 12, 2024 03:31 PM EST
People
Pharma

Bio­Mar­in's chief com­mer­cial of­fi­cer step­ping down, search for suc­ces­sor be­gins

Beth Snyder Bulik

Senior Editor

Bio­Marin’s chief com­mer­cial of­fi­cer Jeff Ajer is leav­ing the com­pa­ny. Bio­Marin is ter­mi­nat­ing his em­ploy­ment “with­out cause,” it said in an SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times